Novozymes creates new biopharmaceutical ingredients business

Published: 24-Apr-2007

Novozymes, the specialist in biotech-based enzymes and micro-organisms, is to create a new biopharmaceutical ingredients business that will develop and manufacture animal-free recombinant ingredients to support biopharmaceutical production.


Novozymes, the specialist in biotech-based enzymes and micro-organisms, is to create a new biopharmaceutical ingredients business that will develop and manufacture animal-free recombinant ingredients to support biopharmaceutical production.

The biopharmaceutical ingredients business is headquartered in Nottingham, UK.

The initial focus of the new business area will be the launch of a range of animal-free recombinant ingredients developed specifically for industrial-scale mammalian cell culture. The range will deliver productivity, compliance and consistency while avoiding the regulatory, quality and performance issues often associated with animal and human-derived raw materials.

The design and manufacture of recombinant ingredients for the biopharma industry is a significant development in terms of Novozymes' traditional business, expanding on the company's science-led approach and its expertise in industrial-scale microbial protein production.

'We have combined Novozymes' expertise in large-scale protein production and supply with a strong science base to provide a range of products specifically developed for biopharmaceutical production,' said Peter Rosholm, recently appointed vice president for the ingredients business area. 'In addition to addressing the need to produce ever-safer biopharmaceuticals, our cell culture range has a secure supply network to deliver ingredients that allow for process optimisation while reducing customers' regulatory and lot testing burdens.'

You may also like